Horizon Pharma Plc Stock Debt To Equity
| HZNPDelisted Stock | USD 100.40 0.13 0.13% |
Horizon Pharma PLC fundamentals help investors to digest information that contributes to Horizon Pharma's financial success or failures. It also enables traders to predict the movement of Horizon Stock. The fundamental analysis module provides a way to measure Horizon Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Horizon Pharma stock.
Horizon |
Horizon Pharma PLC Company Debt To Equity Analysis
Horizon Pharma's Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Current Horizon Pharma Debt To Equity | 0.53 % |
Most of Horizon Pharma's fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Horizon Pharma PLC is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
CompetitionAccording to the company disclosure, Horizon Pharma PLC has a Debt To Equity of 0.533%. This is 99.0% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The debt to equity for all United States stocks is 98.91% higher than that of the company.
Horizon Debt To Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Horizon Pharma's direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Horizon Pharma could also be used in its relative valuation, which is a method of valuing Horizon Pharma by comparing valuation metrics of similar companies.Horizon Pharma is currently under evaluation in debt to equity category among its peers.
Horizon Fundamentals
| Return On Equity | 0.0854 | |||
| Return On Asset | 0.0444 | |||
| Profit Margin | 0.12 % | |||
| Operating Margin | 0.18 % | |||
| Current Valuation | 26.87 B | |||
| Shares Outstanding | 229 M | |||
| Shares Owned By Insiders | 1.18 % | |||
| Shares Owned By Institutions | 98.82 % | |||
| Number Of Shares Shorted | 7.1 M | |||
| Price To Earning | 32.55 X | |||
| Price To Book | 5.10 X | |||
| Price To Sales | 6.93 X | |||
| Revenue | 3.63 B | |||
| Gross Profit | 2.8 B | |||
| EBITDA | 1.11 B | |||
| Net Income | 521.48 M | |||
| Cash And Equivalents | 2.13 B | |||
| Cash Per Share | 9.40 X | |||
| Total Debt | 2.56 B | |||
| Debt To Equity | 0.53 % | |||
| Current Ratio | 3.96 X | |||
| Book Value Per Share | 23.20 X | |||
| Cash Flow From Operations | 1.26 B | |||
| Short Ratio | 2.04 X | |||
| Earnings Per Share | 1.88 X | |||
| Price To Earnings To Growth | 1.00 X | |||
| Target Price | 116.5 | |||
| Number Of Employees | 2.19 K | |||
| Beta | 1.01 | |||
| Market Capitalization | 26.63 B | |||
| Total Asset | 9.11 B | |||
| Retained Earnings | 590.01 M | |||
| Working Capital | 2.7 B | |||
| Current Asset | 1.11 B | |||
| Current Liabilities | 357.55 M | |||
| Z Score | 7.48 | |||
| Net Asset | 9.11 B |
About Horizon Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Horizon Pharma PLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Horizon Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Horizon Pharma PLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Horizon Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Horizon Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Horizon Pharma will appreciate offsetting losses from the drop in the long position's value.Moving together with Horizon Stock
Moving against Horizon Stock
| 0.65 | CSCO | Cisco Systems | PairCorr |
| 0.65 | HPQ | HP Inc | PairCorr |
| 0.61 | KB | KB Financial Group | PairCorr |
| 0.58 | XOM | Exxon Mobil Corp Fiscal Year End 7th of February 2025 | PairCorr |
| 0.49 | BAC | Bank of America Fiscal Year End 10th of January 2025 | PairCorr |
The ability to find closely correlated positions to Horizon Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Horizon Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Horizon Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Horizon Pharma PLC to buy it.
The correlation of Horizon Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Horizon Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Horizon Pharma PLC moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Horizon Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Other Consideration for investing in Horizon Stock
If you are still planning to invest in Horizon Pharma PLC check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Horizon Pharma's history and understand the potential risks before investing.
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |